Biotech
NEW YORK, NY: Data Published in Proceedings of the National Academy of Sciences; Results Suggest Role for ROCK2 Inhibition in Autoimmunity Treatment
...
TUSTIN, CA: Combination of Bavituximab and Sorafenib in Patients With Advanced Liver Cancer Resulted in Increased Cytotoxic T-cell Activation and Other Immune Responses Within Tumors Which Positively Correlated W ...
LONDON, ONTARIO: Advances Made in Cell Pouch(TM) Clinical Development and Positive Outlook for Company's New Therapeutic Cell Technologies
...
LONDON, ONTARIO: Additional Funding to Support COTI-2 Phase 1 Clinical Study
...
TUSTIN, CA: Combining PS-Targeting and Anti-CTLA-4 Antibodies Results in Statistically Significant Improvement in Anti-Tumor Activity as Compared to Anti-CTLA-4 Treatment Alone; Data Support Ability of PS-Targeti ...
SAN FRANCISCO, CA: Third Quarter Collaboration Revenue Increased 234% Year-on-Year to $200.5 Million; Net Income Was $78.0 Million, or $0.96 per Diluted Share; Conference Call Today at 4:30 p.m. Eastern Time
...
SOUTH SAN FRANCISCO, CA: Progress in Priority Portfolio Programs; Investor & Analyst Day Planned for December 12th
...
DUBLIN, IRELAND: Net Sales Increase Three-Fold to $75.1 Million; Adjusted EBITDA of $28.1 Million; Conference Call and Webcast Today, November 6th, at 8:00 a.m. ET
...
